Literature DB >> 34837640

Curcumin Ameliorates Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity Via Suppressing Oxidative Stress and Modulating iNOS, NF-κB, and TNF-α in Rats.

Ghadha Ibrahim Fouad1, Kawkab A Ahmed2.   

Abstract

Doxorubicin (DOX) is one of the widely used anti-tumor drugs. However, DOX-induced cardiotoxicity (DIC) and hepatotoxicity (DIH) are among the side effects that limited its therapeutic efficiency and clinical applicability. This study aimed to investigate the cardioprotective and hepatoprotective potentials of curcumin (CMN)-a bioactive polyphenolic compound-in alleviating DOX-induced cardiotoxicity (DIC) and hepatotoxicity (DIH) in male rats. A single intraperitoneal (i.p.) dose of DOX (20 mg/kg) was used to induce DIC and DIH. DOX-intoxicated rats were co-treated with CMN (100 mg/kg, oral) for 10 days before and 5 days after a single dose of DOX. We studied the anti-inflammatory and anti-oxidative activities of CMN on biochemical and immunohistochemical aspects. DOX disrupted cardiac and hepatic functions and stimulated oxidative stress and inflammation in both tissues that was confirmed biochemically and immunohistochemically. DOX enhanced inflammatory interferon-gamma (IFN-γ) and upregulated immunoexpression of nuclear factor-κB (NF-κB), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-alpha (TNF-α). DOX induced structural alterations in both cardiac and hepatic tissues. CMN demonstrated cardioprotective potential through reducing cardiac troponin I (cTn1) and aspartate amino transaminase (AST). In addition, CMN significantly ameliorated liver function through decreasing alanine amino transaminase (ALT) and, gamma-glutamyl transferase (GGT), total cholesterol (TC), and triglycerides (TG). CMN demonstrated anti-inflammatory potential through decreasing IFN-γ levels and immunoexpression of iNOS, NF-κB, and TNF-α. Histopathologically, CMN restored DOX-associated cardiac and liver structural alterations. CMN showed anti-oxidative and anti-inflammatory potentials in both the cardiac and hepatic tissues. In addition, cTn1, IFN-γ, and AST could be used as blood-based biomarkers.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiotoxicity; Curcumin; Doxorubicin; Hepatotoxicity; Interferon-gamma (IFN-γ); Nuclear factor-κB (NF-κB)

Mesh:

Substances:

Year:  2021        PMID: 34837640     DOI: 10.1007/s12012-021-09710-w

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  59 in total

1.  Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin.

Authors:  Yusuf Kalender; Mustafa Yel; Suna Kalender
Journal:  Toxicology       Date:  2005-01-08       Impact factor: 4.221

Review 2.  The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics.

Authors:  Patrik Prša; Betül Karademir; Gökhan Biçim; Hatem Mahmoud; Inbal Dahan; A Süha Yalçın; Jamal Mahajna; Irina Milisav
Journal:  Biochem Pharmacol       Date:  2019-06-08       Impact factor: 5.858

Review 3.  Oxidative stress injury in doxorubicin-induced cardiotoxicity.

Authors:  Mei Songbo; Hong Lang; Cai Xinyong; Xiao Bin; Zhang Ping; Shao Liang
Journal:  Toxicol Lett       Date:  2019-02-25       Impact factor: 4.372

4.  Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

Authors:  Yoshihiko Ichikawa; Mohsen Ghanefar; Marina Bayeva; Rongxue Wu; Arineh Khechaduri; Sathyamangla V Naga Prasad; R Kannan Mutharasan; Tejaswitha Jairaj Naik; Hossein Ardehali
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

5.  Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.

Authors:  Carlos Galán-Arriola; Manuel Lobo; Jean Paul Vílchez-Tschischke; Gonzalo J López; Antonio de Molina-Iracheta; Claudia Pérez-Martínez; Jaume Agüero; Rodrigo Fernández-Jiménez; Ana Martín-García; Eduardo Oliver; Rocío Villena-Gutierrez; Gonzalo Pizarro; Pedro L Sánchez; Valentin Fuster; Javier Sánchez-González; Borja Ibanez
Journal:  J Am Coll Cardiol       Date:  2019-02-26       Impact factor: 24.094

6.  Neuroprotective Potential of Berberine Against Doxorubicin-Induced Toxicity in Rat's Brain.

Authors:  Ghadha Ibrahim Fouad; Kawkab A Ahmed
Journal:  Neurochem Res       Date:  2021-08-17       Impact factor: 3.996

7.  Self-Maintenance of Cardiac Resident Reparative Macrophages Attenuates Doxorubicin-Induced Cardiomyopathy Through the SR-A1-c-Myc Axis.

Authors:  Hanwen Zhang; Andi Xu; Xuan Sun; Yaqing Yang; Lai Zhang; Hui Bai; Jingjing Ben; Xudong Zhu; Xiaoyu Li; Qing Yang; Zidun Wang; Wei Wu; Di Yang; Yongjie Zhang; Yong Xu; Qi Chen
Journal:  Circ Res       Date:  2020-05-29       Impact factor: 17.367

Review 8.  Cardiomyocyte death in doxorubicin-induced cardiotoxicity.

Authors:  Yi-Wei Zhang; Jianjian Shi; Yuan-Jian Li; Lei Wei
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-10-29       Impact factor: 4.291

Review 9.  Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Authors:  Ravi V J Chari
Journal:  Acc Chem Res       Date:  2007-08-18       Impact factor: 22.384

10.  Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.

Authors:  Elizabeth A M Feijen; Wendy M Leisenring; Kayla L Stratton; Kirsten K Ness; Helena J H van der Pal; Elvira C van Dalen; Gregory T Armstrong; Gregory J Aune; Daniel M Green; Melissa M Hudson; Jacqueline Loonen; Kevin C Oeffinger; Leslie L Robison; Yutaka Yasui; Leontien C M Kremer; Eric J Chow
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

View more
  1 in total

1.  Can Dietary Nutrients Prevent Cancer Chemotherapy-Induced Cardiotoxicity? An Evidence Mapping of Human Studies and Animal Models.

Authors:  Xin-Yu Zhang; Ke-Lu Yang; Yang Li; Yang Zhao; Ke-Wei Jiang; Quan Wang; Xiao-Nan Liu
Journal:  Front Cardiovasc Med       Date:  2022-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.